Sarcopenia is a medical condition characterized by the loss of muscle mass, strength, and function, particularly in older adults. they naturally experience a gradual loss of muscle mass and function, which predisposes them to sarcopenia as people age. The number of individuals at risk of developing sarcopenia is increasing steadily with the world's population aging. This demographic shift directly drives the demand for sarcopenia treatment options. The increasing prevalence of the condition means that more individuals require diagnosis and treatment, creating a larger patient pool for the global sarcopenia treatment market.
Access full Report @ https://www.databridgemarketresearch.com/pt/reports/global-sarcopenia-treatment-market
People are living longer lives with advances in healthcare and medicine. However, as individuals age, they are more likely to develop sarcopenia. This longer life expectancy contributes to the overall prevalence of the condition. Chronic illnesses such as diabetes, cardiovascular disease, and cancer can lead to muscle loss and contribute to the development of sarcopenia. The increasing incidence of these conditions has a direct impact on the rising prevalence of sarcopenia.
Key Findings of the Study
Growing Awareness of Sarcopenia and its Detrimental Effects on Health
The growing awareness of sarcopenia and its detrimental effects on health is a significant development in the field of healthcare and aging. There has been a significant increase in research and publications related to sarcopenia. Scientific studies, medical journals, and publications have provided healthcare professionals with valuable information about the condition's prevalence, diagnosis, and consequences. Medical schools and training programs have incorporated sarcopenia into their curricula. This ensures that healthcare professionals, including doctors, nurses, and physical therapists, receive education about sarcopenia, its risk factors, and management strategies.
Various advocacy groups and organizations have been actively promoting awareness about sarcopenia. These groups often collaborate with healthcare professionals to educate the public about the conditions risks and the importance of early diagnosis and intervention. Sarcopenia has received increased coverage in mainstream media, including articles, news reports, and documentaries. This exposure has helped raise awareness among the general public.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route Of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland and Rest of Europe, China, Japan, Australia, India, South Korea, New Zealand, Singapore, Thailand, Malaysia, Vietnam, Taiwan, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Bahrain, Qatar, Oman and Rest of Middle East and Africa
|
|
Market Players Covered
|
Abbott. (U.S.), Nestlé Health Science (A subsidary of Nestlé S.A.) (Switzerland), Novartis AG (Switzerland), Sanofi (France), Haleon Group of Companies.(England), BASF SE (Germany), DSM (Netherlands), Fermenta Biotech Limited (India), AstaReal Co., Ltd.(Japan), Metagenics (U.S.), BioThrive Sciences.(U.S.), Wellona Pharma (India), The Vitamin Company India (India), Biogen SA (South Africa), Healing Pharma India Pvt. Ltd.(India), MyMD Pharmaceuticals (U.S.), ONCOCROSS CO.,LTD (South Korea), Dystrogen Therapeutics Corp (U.S.), OPKO Health, Inc.(U.S.), NMD PHARMA A/S (Denmark), ImmunoForge Inc (South Korea), Regeneron Pharmaceuticals Inc.(U.S.), Biophytis (France), ARMGO Pharma, Inc.(U.S.), Rejuvenate Biomed NV. (Belgium) and among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The global sarcopenia treatment market is segmented into seven notable segments such as treatment type, type, stages, route of administration, gender, end user, and distribution channel.
- On the basis of treatment type, the global sarcopenia treatment market is segmented into vitamin/dietary supplements, medications, and others.
In 2023, the vitamin/dietary supplements segment is expected to dominate the Global Sarcopenia Treatment Market
In 2023, the vitamin/dietary supplements segment is expected to dominate the market due to its increasing demand among the population, with a market share of 47.83%.
- On the basis of type, the global sarcopenia treatment market is segmented into primary sarcopenia, and secondary sarcopenia.
In 2023, the primary sarcopenia segment is expected to dominate the global sarcopenia treatment market
In 2023, the primary sarcopenia segment is expected to dominate the market due to its rising prevalence among population, with a market share of 58.72%.
- On the basis of stages, the global sarcopenia treatment market is segmented into pre-sarcopenia, sarcopenia, and severe sarcopenia. in 2023, the pre-sarcopenia segment is expected to dominate the market with a market share of 44.85%.
- on the basis of route of administration, the global sarcopenia treatment market is segmented into oral, injectables, and others. in 2023, the oral segment is expected to dominate the market with a market share of 52.94%.
- on the basis of gender, the global sarcopenia treatment market is segmented into male, and female. in 2023, the male segment is expected to dominate the market with a market share of 61.55%.
- on the basis of end user, the global sarcopenia treatment market is segmented into hospitals, specialty clinics, home healthcare, and others. in 2023, the hospitals segment is expected to dominate the market with a market share of 51.25%.
- on the basis of distribution channel, the global sarcopenia treatment market is segmented into direct tenders, retail sales, and others. in 2023, the direct tender segment is expected to dominate the market with a market share of 62.28%.
Major Players
Data Bridge Market Research analysis Abbott. (U.S.), Nestlé Health Science (A subsidary of Nestlé S.A.) (Switzerland), Novartis AG (Switzerland), Sanofi (France), Haleon Group of Companies. (England) as the major market players in the sarcopenia treatment market.
Market Development
- In August 2023, Haleon, a global leader in consumer health, and Direct Relief, announced that a humanitarian aid organization, have agreed to a multi-year commitment to expand access to everyday health for underserved communities while boosting emergency response and preparedness efforts around the world. This will increase the company brand image among others.
- In June 2023, Sanofi announced that its consumer healthcare business unit had launched a new open innovation portal, allowing the wider supply chain community to submit their creative, disruptive, and game-changing solutions to meet the challenges of an ever-evolving consumer healthcare landscape. This helps the organization in developing more revenue.
- In February 2023, Nestlé Health Science announced that they entered into a research collaboration with EraCal Therapeutics, to identify novel nutraceuticals relevant to controlling food intake. This will increase the company product portfolio and overall revenue
- In November 2022, Abbott announced that it has been awarded by the Consumer Technology Association (CTA) with three CES 2023 innovation awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide.
- In July 2022, AstaReal Co., Ltd. announced that AstaReal Astaxanthin was awarded cognitive function ingredient of the year 2022. This helps the organization in developing brand image among others.
Regional Analysis
Geographically, the countries covered in the global sarcopenia treatment market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland and Rest of Europe, China, Japan, Australia, India, South Korea, New Zealand, Singapore, Thailand, Malaysia, Vietnam, Taiwan, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Bahrain, Qatar, Oman and Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is the dominating region in global sarcopenia treatment market
North America is market owing to the higher level of investments by various manufacturers and increasing demand for pharmaceutical products manufacturing in the region.
Asia-Pacific is estimated to be the fastest growing region in the global sarcopenia treatment market in the forecast period 2023 - 2030
Asia-Pacific is expected to be fastest growing in market in due to strategic initiatives taken by major market players.
For more detailed information about the global sarcopenia treatment market report, click here – https://www.databridgemarketresearch.com/pt/reports/global-sarcopenia-treatment-market
